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Background: Data are scarce on the long-term clinical outcomes of perinatally HIV-infected 
children and adolescents receiving antiretroviral therapy (ART) in low/middle-income 
countries. We assessed the incidence of mortality before (early) and after (late) 6-month of 
ART and of the composite outcome of new/recurrent AIDS-defining-event or death >6 
months after ART start (late AIDS/death) and their associated factors. 
Methods: Study population was perinatally HIV-infected children (≤18 years) initiating ART 
within the Program for HIV Prevention and Treatment observational cohort (NCT00433030). 
Factors associated with late AIDS/death were assessed using competing risk regression 
models accounting for loss-to-follow-up, and included baseline and time-updated variables.  
Results: Among 619 children, “early” mortality incidence was 99 deaths per 1000-PYFU 
(95%CI; 69-142) and “late” mortality 6 per 1000-PYFU (95%CI; 4-9). Of the 553 children 
alive >6 months after ART initiation, median age at ART initiation was 6.4 years, CD4% 
8.2% and HIV-RNA 5.1 log10 copies/mL. 38 (7%) children developed late AIDS/death after 
median time of 3.3 years: 24 died and 24 experienced new/recurrent AIDS-defining-events 
(10 subsequently died). Factors independently associated with late AIDS/death were: current 
age ≥13 years (adjusted sub-distribution hazard-ratio 4.9; 95%CI; 2.4-10.1), HIV-RNA 
always ≥400 copies/mL (12.3; 4.0-37.6), BMI-z-score always <-2 SD (13.7; 3.4-55.7), and 
hemoglobin <8g/dL at least once (4.6; 2.0-10.5). 
Conclusions: After the initial 6 months of ART, being an adolescent, persistent viremia, poor 
nutritional status and severe anemia were associated with poor clinical outcomes. This 
supports the need for novel interventions that target children, particularly adolescents with 
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Background: Data are scarce on the long-term clinical outcomes of perinatally HIV-
infected children and adolescents receiving antiretroviral therapy (ART) in low/middle-
income countries. We assessed the incidence of mortality before (early) and after (late) 
6-month of ART and of the composite outcome of new/recurrent AIDS-defining-event 
or death >6 months after ART start (late AIDS/death) and their associated factors. 
Methods: Study population was perinatally HIV-infected children (≤18 years) 
initiating ART within the Program for HIV Prevention and Treatment observational 
cohort (NCT00433030). Factors associated with late AIDS/death were assessed using 
competing risk regression models accounting for loss-to-follow-up, and included 
baseline and time-updated variables.  
Results: Among 619 children, “early” mortality incidence was 99 deaths per 1000-
PYFU (95%CI; 69-142) and “late” mortality 6 per 1000-PYFU (95%CI; 4-9). Of the 
553 children alive >6 months after ART initiation, median age at ART initiation was 
6.4 years, CD4% 8.2% and HIV-RNA 5.1 log10 copies/mL. 38 (7%) children 
developed late AIDS/death after median time of 3.3 years: 24 died and 24 experienced 
new/recurrent AIDS-defining-events (10 subsequently died). Factors independently 
associated with late AIDS/death were: current age ≥13 years (adjusted sub-distribution 
hazard-ratio 4.9; 95%CI; 2.4-10.1), HIV-RNA always ≥400 copies/mL (12.3; 4.0-37.6), 
BMI-z-score always <-2 SD (13.7; 3.4-55.7), and hemoglobin <8g/dL at least once 
(4.6; 2.0-10.5). 
Conclusions: After the initial 6 months of ART, being an adolescent, persistent 
viremia, poor nutritional status and severe anemia were associated with poor clinical 
outcomes. This supports the need for novel interventions that target children, 
particularly adolescents with poor growth and uncontrolled viremia. 
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In low and middle-income countries, a growing number of perinatally infected children 
are reaching adolescence and adulthood as the result of the scale-up of ART programs 
during the last decade. However, few pediatric cohorts have been sufficiently followed  
to investigate clinical outcomes during adolescence1-3. Maintaining ART adherence 
throughout adolescence is challenging4,5 and poor outcomes during this vulnerable 
period have been reported6-8.  
Using data from a cohort of HIV-infected children receiving ART over a 14-year 
period within a network of 39 public hospitals throughout Thailand, we estimated the 
incidence of mortality before (“early”) and after (“late”) 6-month of ART initiation and 
of a composite outcome defined as new/recurrent AIDS-defining-events or death after 6 
month of ART start (late AIDS/death). We also studied factors associated with the risk 





We included data on all perinatally HIV-infected children (≤18 years) who initiated 
ART between January 1, 1999 and June 30, 2013 and were followed until July 31, 
2014, as part of the Program for HIV Prevention and Treatment (PHPT) prospective 
observational cohort (NCT00433030)9,10. Children were enrolled with 
parental/caregiver consent, and personal assent if age ≥8 years. ART and laboratory 
monitoring were provided free of charge. 
The study protocol was approved by the ethics committees at the Thai Ministry of 
Public Health, local hospitals and the Faculty of Associated Medical Sciences, Chiang 
Mai University, Thailand.  
Follow-up  
Clinical visits were scheduled at ART initiation, at 2 weeks, 1, 3 and 6 months, and 
then every 6 months thereafter. CD4 and virology testing was performed at start of 
ART and every 6 months thereafter. HIV-genotyping was performed in case of 
virological failure using the Agence Nationale de Recherches sur le SIDA (ANRS) in-
house technique (AC11-Resistance Study Group PCR and Sequencing Procedures)11.  
Loss-to-follow-up (LTFU) was defined as a missed scheduled visit and no contact for 
at least 9 months since last appointment. Attempt to contact LTFU children were made 
with telephone calls and home visits. Voluntary withdrawal was defined as notified exit 
from study, including notified transfer to adult care.  
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Antiretroviral treatment  
Nucleoside reverse-transcriptase inhibitor (NRTI) dual therapy was provided from 
1999, mostly zidovudine and didanosine. Protease inhibitor (PI) became available in 
2002 and non-nucleoside reverse-transcriptase inhibitors (NNRTI) in 2003. Children 
initially on dual NRTIs could be switched to triple therapy when it became available. 
Children who experienced drug toxicity or treatment failure received alternative 
regimens as needed. 
Outcomes and analysis of the risk factors 
Events occurring during the first 6 months after ART start were defined as “early”, and 
those occurring after 6 months were defined as “late”. The outcomes of interest were 
early deaths, late deaths, and a composite outcome defined as late new/recurrent AIDS-
defining-events or death (late AIDS/death). All events were documented by the 
responsible site physicians. Clinical records were reviewed by 2 independent 
physicians, and causes of death classified according to the International Classification 
of Diseases 10. 
Factors associated with mortality within this cohort after median follow-up of 4.5 years 
have been previously described9. We assessed here factors associated with the risk of 
occurrence of late AIDS or death. Children were considered at risk from 6 months after 
ART start and their follow-up time was censored at the earliest date of first AIDS 
event, death or at last visit. 
Analysis of factors associated with late AIDS/death included baseline characteristics at 
ART start and time-updated variables. Baseline characteristics were based on the 
closest assessment available within one year before ART start, or if not available, 
within 15 days after. Weight-for-age and height-for-age z-scores were computed based 
on Thai references12 and BMI-for-age z-scores based on WHO curves13,14. For time-
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updated variables, all measurements after 6 months of ART were used and 
dichotomized as follow: adolescent (current age ≥13 years, corresponding to the age at 
puberty in this population15), BMI-for-age z-score always <-2 standard deviations (SD) 
and ever severely anaemic (hemoglobin <8 g/dL). HIV-RNA viral load was categorized 
in 3 categories: always suppressed (<400 copies/mL), occasional viremia (≥1 viral load 
measurement ≥ 400 copies/mL), and never suppressed (all viral load measurements ≥400 
copies/mL). 
Statistical analysis  
Crude mortality rates are provided with their 95% confidence intervals (CIs) based on 
Poisson distribution. Incidences are reported in events per 1000 person-years of follow-
up (PYFU).  
Factors associated with the late composite outcome of AIDS or death used Fine-Gray 
competing risk regression models accounting for LTFU as a competing event16, with a 
backward stepwise selection. In the multivariable analysis, only time-updated variables 
were considered if baseline and time-updated variables were collinear and both were 
associated with the outcome (P<0.20) in the univariable analysis. Associations were 
reported using subdistribution hazard-ratio (SHR)17. 
To avoid loss of information and biased estimates because of missing data, we imputed 
missing values with linear interpolation for time-updated variables18. Sensitivity 
analyses on complete cases and with adjustment on age and calendar year at ART 
initiation, and using HIV-RNA ≥1000 copies/mL threshold instead of 400 copies/mL, 
were also performed. All tests were two-sided and P<0.05 was considered statistically 




Overall incidence of mortality 
Over the 14-year study period, 619 children ≤18 years initiated ART within the cohort. 
The median (IQR) follow-up duration was 7.7 years (3.5-9.8) corresponding to 4,320 
PYFU. Overall, 53 (9%) children died during follow-up, 144 (23%) were LTFU and 
152 (25%) voluntarily withdrew, most often due to notified self-referral to another 
hospital. The median follow-up duration among children who died was 0.4 years (0.1-
2.2), 6.5 years (2.2-8.5) for those LTFU, and 4.9 years (1.5-8.7) for those who 
withdrew. The crude incidence (95%CI) of death was 12 (9-16) per 1000-PYFU, Table 
1.  
Early deaths 
A total of 29 deaths occurred within the first 6 months after ART initiation 
corresponding to an incidence of early death of 99 (69 to 142) per 1000-PYFU (Table 
1).  
For the analysis of late events, 553 (89%) children were included, 66 children were 
excluded due to <6 months follow-up after ART start (29 deaths, 15 LTFU and 22 
withdrawals). Characteristics at ART initiation are described in Table 2, 302 (55%) 
were female, median age 6.4 years [IQR, 2.2-9.6], and BMI-for-age z-score -0.8 [-1.9 
to 0.1]. Their median follow-up was 8.1 years [4.9-9.9]. Half of the children were CDC 
stage B or C, median CD4% was 8.2% [2.5-16.3] and HIV-RNA load 5.1 log10 
copies/mL [4.7-5.6]. The majority, 441 (80%) children initiated NNRTI-based ART, 56 




A total of 24 (4%) children died after a median time of 2.6 years (1.3-6.3). Crude 
incidence (95%CI) of late death was 6 (4-9) per 1000-PYFU (Table 1). Of these deaths, 
14 (58%) occurred in hospitals, 8 (33%) at home, and 2 (8%) elsewhere. The median 
age at death was 11.9 years (IQR, 2.6-14.4). Causes of death were mostly HIV-related: 
wasting syndrome (5) cryptococcal meningitis (4), septic shock (3), respiratory failure 
(3), cerebral hemorrhage (2), bacterial pneumopathy (1), brain abscess (1), complete 
heart block (1) and congestive heart failure (1). Three external causes of death included 
drowning (2) and suicide (1). 
Late new/recurrent AIDS defining event.  
Twenty-four patients experienced a total of 45 new/recurrent AIDS-defining-events 
(Table 1). Median time to first new/recurrent AIDS-defining-event was 5.1 years after 
ART initiation (1.7-7.2). Crude incidence (95%CI) of new/recurrent AIDS-defining-
events 6 (4 to 8) per 1000-PYFU. First AIDS-defining-events were: tuberculosis (6), 
pneumonia (6), penicilliosis (4), cryptococcal meningitis (2), septic shock (2) and one 
each of the following: brain abscess, meningitis, encephalopathy, and pneumocystosis. 
Late composite outcome: new/reccurent AIDS-defining-event or death 
A total of 38 (7%) children met the late composite outcome of AIDS/death, the first 
event was AIDS in 24 children (10 went on to subsequently die) and 14 died without a 
preceeding AIDS event. Median time to the first composite outcome was 3.3 years 
(1.3-6.3) after ART start, with a crude incidence 9 (7 to 12) per 1000-PYFU (Table 1).  
Factors associated with the late AIDS/deaths are presented in Table 2.  In multivariable 
analysis, after adjustment on time-updated variables, factors independently associated 
with the composite outcome were: current age ≥13 years (adjusted SHR [aSHR], 4.9; 
95%CI; 2.4-10.1), HIV-RNA load always ≥400 copies/mL (aSHR=12.3; 4.0-37.6), 
BMI-z-score always below -2 SD (aSHR=13.7; 3.4-55.7), and ever experiencing severe 
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anemia (aSHR=4.6; 2.0-10.5). There was no interaction between current age and HIV-
RNA load. Results of sensitivity analyses were similar when using complete case 
analysis, or with adjustment on age and calendar year at ART initiation, or when using 
HIV-RNA ≥1,000 threshold instead of 400 copies/mL (data not shown).  
HIV genotypic resistance testing was performed at least once in 30% (167/553) of 
children, 47% (18/38) of those who reached the composite outcome vs. 29% (149/515) 
of those who did not (p=0.026). Median time from ART initiation to first genotyping 
was 3.3 years (2.0-5.1) among those who reached the composite outcome versus 2.0 
years (1.3-4.7) in the others (p=0.200). At the time of first HIV genotyping, 80% of 
children had NRTI mutations, 77% NNRTI mutations and 3% PI mutations with no 
difference whether they met the composite outcome or not (p=0.758). However,  there 
was a trend suggesting children with the composite outcome were more likely to carry 





Our study indicates that the incidence of mortality in HIV-infected children and 
adolescents dramatically decreased after the first 6 months of ART as it was 16 times 
lower than during the first 6 months. It emphasizes the importance of splitting early 
and late mortality analyses. After adjustment, being an adolescent, having persistent 
severely low BMI, never achieving viral suppression<400 cps/mL and one or more 
episode of severe anemia 6 months after ART start were independently associated with  
late new/recurrent AIDS-defining-events or deaths.  
The overall mortality incidence in our study was low at 12 per 1000-PYFU, within the 
range 6–15 per 1000-PYFU reported in other pediatric cohorts in developed 
countries2,19, but lower than the 17–144 per 1000-PYFU in developing countries3,20-26. 
Also, the dramatic decrease in mortality after a few months of ART is consistent with 
previous studies19-22. Yet, rates are difficult to compare since mortality depends on age 
at ART initiation which varies across cohorts. Indeed, several studies indicate lower 
mortality in children initiating ART at older ages, a selected population of long-term 
survivors3,19,21,25,26. In a previous assessment within the same cohort after 4.5-year 
follow-up, the late mortality incidence was similar than in this updated analysis, 
reflecting a stable mortality trend over time among those on long-term ART9.  
Children meeting the composite outcome had their first HIV genotypic resistance test 
later than those who did not reach the outcome, which may reflect delayed detection of 
treatment failure leading to the accumulation of resistance mutations to ART classes.  
As in any cohort, unreported AIDS-events or mortality among children LTFU may lead 
to an underestimation of events27. Taking into account LTFU as a competing risk 
should limit this bias.  
13 
 
Since the number of deaths was relatively small and deaths were mainly related to 
AIDS-defining-events, we used a combined outcome of AIDS-defining-events or 
deaths to increase the statistical power in identifying most at-risk children.  
In previous studies over shorter follow-up periods, baseline characteristics at ART 
initiation such as young age, advanced disease stage, poor immunological status, 
anemia and poor nutritional status were associated with mortality3,9,19-23,28. However, as 
follow-up lengthens, the significance of baseline characteristics fades while the relative 
contribution of time-updated variables increases. In our study, using time-updated 
variables, we found that children experiencing persistent poor nutritional status or 
severe anemia were at higher risk of adverse outcome. These factors are easily 
accessible to clinicians, even with limited laboratory facilities.  
Our analysis clearly shows that adolescence was an independent predictor of late 
new/recurrent AIDS-defining-event or death with a risk nearly 5 times higher than in 
younger children. This association remained even after adjustment on viral load, 
suggesting the potential role of unadjusted confounders related to poor adherence. In a 
cohort-study in Uganda, over a median 28-month follow-up, the crude mortality rate 
was higher for adolescents than for younger children6. Also, an increasing trend in 
mortality has been described among perinatally HIV-infected adolescents reaching 
adulthood in England29. Maintaining ART adherence is challenging especially when 
children stop relying on their caregivers for their daily medication4,30,31. In a context 
where third-line ART is not readily available, this may result in adverse outcomes, 
including death32,33.  
Our results emphasize factors that should trigger closer follow-up and highlight the 
need for novel interventions to support the increasing group of adolescents at risk of 
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